{"schema_version":"secwatch.filing_event.v1","accession":"0001534969-22-000129","form_type":"8-K","ticker":"SERA","cik":"0001534969","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.065221+00:00","generated_at":"2026-06-22T01:11:52.586262+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sera Prognostics Q3 2022: Revenue $87k, Net Loss $10.7M; Banner Health contract signed","bullets":["Q3 revenue $87,000, up from $23,000 YoY; net loss $10.7M vs $9.9M.","Operating expenses $11.3M, up from $9.5M; R&D $4.2M, SG&A $7.0M.","Cash, equivalents & securities $111.2M at Sept 30, 2022.","Banner Health signed for PreTRM test under Medicaid plan (~300k members); revenue possible Q4 2022.","PRIME study on track; interim look expected 2023; preeclampsia validation data by year-end 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-22-000129","json":"https://secwatch.observer/filing/0001534969-22-000129.json","markdown":"https://secwatch.observer/filing/0001534969-22-000129.md","text":"https://secwatch.observer/filing/0001534969-22-000129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496922000129/0001534969-22-000129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496922000129/sera-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:11:52.586262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2fb0a6464d01953103a85b1bd56a8fbfe0fab40d","claim":"SERA PROGNOSTICS, INC. reported the third quarter ended September 30, 2022 results: revenue $87,000, net income $10.7 million.","evidence_excerpt":"traction that we believe will create a more significant impact on our top-line results in 2023 and beyond.” Third Quarter 2022 Financial Results Third quarter 2022 revenue of $87,000 compared to $23,000 for the same period of 2021. Total operating expenses were $11.3 million, up from $9.5 million for the third quarter of 2021. Research and development expenses","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534969/000153496922000129/0001534969-22-000129-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$87,000"},{"label":"Net income","value":"$10.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}